Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma

Summary

This is a prospective, single-centre, observational study. The analysis of samples of pancreatic tumours and/or metastases taken during biopsy or surgery will lead to the determination of the level of expression of convertases in patients with pancreatic cancer and could be used as an additional prognostic means reinforcing those currently used.

Eligibility

Inclusion Criteria:

1. Age ≥ 18 years.
2. Pancreatic adenocarcinoma (suspected on radiological assessment or histologically proven):

   1. Indication for biopsy of metastasis(es) performed as part of standard care for patients who already have a histologically confirmed diagnosis of pancreatic cancer.
   2. Indication for pancreatic surgery or metastasis(es) carried out as part of standard care for patients with a suspicion of pancreatic cancer on radiological assessment or who already have a confirmed histological diagnosis of pancreatic cancer.
3. Whatever the stage of the disease.
4. Whatever the type of treatment proposed (systemic, surgery, radiotherapy, etc.).
5. Patient who has never received systemic treatment or advanced radiotherapy.
6. WHO 0-1-2.
7. Life expectancy \> 3 months.
8. Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
9. Patient affiliated to a social security scheme in compliance with Article 1121-11 of the French Public Health Code.

Exclusion Criteria:

1. Indication for biopsy for primary diagnosis of pancreatic cancer
2. No indication for treatment of pancreatic cancer.
3. Adjuvant/neoadjuvant chemotherapy completed less than 6 months ago in the case of patients with recurrent disease.
4. Patient already included in the study.
5. Geographical, social or psychological factors rendering the patient unable to undergo study monitoring and procedures.

Conditions2

Browse More Trials